293 related articles for article (PubMed ID: 33606577)
21. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
22. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
23. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Boutry C; Hastie A; Diez-Domingo J; Tinoco JC; Yu CJ; Andrews C; Beytout J; Caso C; Cheng HS; Cheong HJ; Choo EJ; Curiac D; Di Paolo E; Dionne M; Eckermann T; Esen M; Ferguson M; Ghesquiere W; Hwang SJ; Avelino-Silva TJ; Kosina P; Liu CS; Markkula J; Moeckesch B; Murta de Oliveira C; Park DW; Pauksens K; Pirrotta P; Plassmann G; Pretswell C; Rombo L; Salaun B; Sanmartin Berglund J; Schenkenberger I; Schwarz T; Shi M; Ukkonen B; Zahaf T; Zerbini C; Schuind A; Cunningham AL;
Clin Infect Dis; 2022 Apr; 74(8):1459-1467. PubMed ID: 34283213
[TBL] [Abstract][Full Text] [Related]
24. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
25. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing.
Lee C; Jiang N; Tang H; Ye C; Yuan Y; Curran D
Hum Vaccin Immunother; 2021 Oct; 17(10):3735-3746. PubMed ID: 34310268
[TBL] [Abstract][Full Text] [Related]
26. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials.
Colindres R; Wascotte V; Brecx A; Clarke C; Hervé C; Kim JH; Levin MJ; Oostvogels L; Zahaf T; Schuind A; Cunningham AL
Hum Vaccin Immunother; 2020 Nov; 16(11):2628-2633. PubMed ID: 32347767
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
[TBL] [Abstract][Full Text] [Related]
28. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.
Volpi A; Boccalini S; Dari S; Clarke C; Curran D; Loiacono I; Pitrelli A; Puggina A; Tosatto R; Van Oorschot D; Franco E
Hum Vaccin Immunother; 2020; 16(2):327-334. PubMed ID: 31442095
[TBL] [Abstract][Full Text] [Related]
29. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
Curran D; Matthews S; Rowley SD; Young JH; Bastidas A; Anagnostopoulos A; Barista I; Chandrasekar PH; Dickinson M; El Idrissi M; Heras I; Milliken ST; Monserrat Coll J; Navarro Matilla MB; Oostvogels L; Piątkowska-Jakubas B; Quiel D; Sabry W; Schwartz S; Selleslag DLD; Sullivan KM; Theunissen K; Yegin ZA; Yeh SP; Zaja F; Szer J;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2474-2481. PubMed ID: 31394276
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
[TBL] [Abstract][Full Text] [Related]
32. [Vaccination against herpes zoster].
Larsen CS; Helleberg M
Ugeskr Laeger; 2021 Nov; 183(47):. PubMed ID: 34851258
[TBL] [Abstract][Full Text] [Related]
33. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
34. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
[TBL] [Abstract][Full Text] [Related]
35. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older.
Curran D; Oostvogels L; Heineman T; Matthews S; McElhaney J; McNeil S; Diez-Domingo J; Lal H; Andrews C; Athan E; Berglund J; Campora L; de Looze F; Korhonen T; Leung E; Levin M; Volpi A; Johnson RW;
J Gerontol A Biol Sci Med Sci; 2019 Jul; 74(8):1231-1238. PubMed ID: 29955836
[TBL] [Abstract][Full Text] [Related]
36. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.
Klein NP; Bartlett J; Fireman B; Marks MA; Hansen J; Lewis E; Aukes L; Saddier P
Vaccine; 2019 Aug; 37(36):5422-5427. PubMed ID: 31301920
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
[TBL] [Abstract][Full Text] [Related]
38. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
[TBL] [Abstract][Full Text] [Related]
39. Herpes Zoster Vaccines.
Harbecke R; Cohen JI; Oxman MN
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
[TBL] [Abstract][Full Text] [Related]
40. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
